On 9 November 2026 the US Food and Drug Administration required every holder of a glucagon-like peptide-1 receptor agonist (GLP-1 RA) application to add the potential increased risk of non-arteritic anterior ischaemic optic neuropathy (NAION) to the Warnings and Precautions section of labelling [1]. The instruction is class-wide. It covers exenatide, liraglutide, dulaglutide, the lixisenatide–insulin glargine combination Soliqua, semaglutide, the dual GIP and GLP-1 agonist tirzepatide, and orforglipron, the oral small-molecule GLP-1 RA approved earlier this year as Foundayo [1].
NAION is rare, and the absolute risk remains small. FDA's meta-analysis of 126 randomised trials found 6.4 events per 100,000 person-years with a GLP-1 RA, against 3.8 with placebo or another glucose-lowering medicine [1]. What matters for pharmacovigilance is how the decision was reached. The US warning is a class-level change built from a pooled clinical-trial analysis and real-world evidence, not from spontaneous reports alone. It also arrives after more than two years of mixed observational literature, and after the European Medicines Agency had already concluded, in June 2025, that NAION is a very rare adverse reaction of semaglutide [2]. Sponsors of marketed and pipeline incretins now have to update reference safety information, expectedness, case follow-up and periodic reports — and, in many programmes, trial consent — in a landscape that is still not fully aligned across regions or products.

A rare event in a high-risk population
NAION is caused by reduced blood flow to the optic disc. It typically presents as sudden, painless loss of vision in one eye, often noticed on waking, sometimes with a visual-field defect, colour distortion or reduced central sharpness [1][6]. There is no proven treatment that restores vision. Patients who have had NAION in one eye are at increased risk in the other [1].
The background rate is low but not trivial, and it is higher in the people who are prescribed these medicines. FDA cites a published incidence of 2.3 to 10.2 cases per 100,000 persons per year in adults older than 50 [1]. The UK Medicines and Healthcare products Regulatory Agency (MHRA) notes that estimates in type 2 diabetes range more widely, from 11.4 to 82 per 100,000 person-years, reflecting differences in case definition and setting [6]. Established risk factors include diabetes, hypertension, smoking, sleep apnoea, anaemia and kidney disease [1][6]. An anatomical predisposition — a crowded optic disc, often called a "disc at risk" — is the main ocular risk factor; Australia's Advisory Committee on Medicines has noted that this feature is present in approximately 97% of NAION cases [8]. Those overlaps are the central difficulty of the signal: the indicated populations already carry much of the background risk.
From a single-centre study to a class warning
The modern signal began in July 2024, when Hathaway and colleagues reported a retrospective matched cohort from a single US tertiary neuro-ophthalmology practice [3]. Semaglutide was associated with a higher NAION risk in patients with type 2 diabetes (hazard ratio [HR] 4.28; 95% confidence interval [CI] 1.62–11.29) and in a separate overweight or obese cohort (HR 7.64; 95% CI 2.21–26.36) [3]. The 36-month cumulative incidence in the diabetes cohort was 8.9% with semaglutide versus 1.8% without it — orders of magnitude above population rates — which is the clearest sign that a tertiary referral practice is a poor place from which to estimate absolute risk. The confidence intervals were wide, residual confounding was likely, and the authors described the work as generating a hypothesis rather than establishing causation [3]. FDA identified several limitations but judged that further assessment was warranted [1].
Two Danish analyses then moved the question into population registries. Grauslund and colleagues reported a 2.19-fold higher five-year hazard with once-weekly semaglutide in 424,152 people with type 2 diabetes [9]. On 16 December 2024 the Danish Medicines Agency asked the EMA Pharmacovigilance Risk Assessment Committee (PRAC) to assess the findings [4]. A subsequent Danish–Norwegian new-user study by Simonsen and colleagues, comparing semaglutide with sodium-glucose co-transporter-2 (SGLT-2) inhibitors, found a pooled adjusted HR of 2.81 (95% CI 1.67–4.75), or 1.41 additional cases per 10,000 person-years [10].
Larger active-comparator studies followed, with more modest effect sizes. Tesfaye, Patorno and colleagues, in a US claims analysis of 482,912 matched pairs, reported an HR of 1.85 (95% CI 1.51–2.27) versus SGLT-2 inhibitors [11]. In the UK Clinical Practice Research Datalink, Noh, Azoulay and colleagues found a one-year risk ratio of 2.56 (95% CI 1.44–4.86) versus dipeptidyl peptidase-4 (DPP-4) inhibitors; the excess was concentrated in the first six months and was higher when haemoglobin A1c fell by at least one percentage point [12].
The literature is not uniform. Chou, Cai and Abbass and their colleagues reported no significant increase, or an increase only under a narrower case definition, and one five-year relative risk below one [13][14][15]. MHRA later recorded that its expert advisory group, while agreeing to update UK product information for semaglutide, noted the conflicting evidence [6]. Key study designs and estimates are summarised in the table below.

| Study | Design and population | Comparator | Effect estimate (95% CI) | Source |
|---|---|---|---|---|
| Hathaway et al., 2024 | Single-centre US neuro-ophthalmology cohort; T2D and, separately, overweight or obesity | Non-GLP-1 RA antidiabetic or weight-loss medicines | T2D: HR 4.28 (1.62–11.29); overweight or obesity: HR 7.64 (2.21–26.36) | [3] |
| Grauslund et al., 2024 | Danish registry cohort, 424,152 people with T2D | No once-weekly semaglutide | HR 2.19 (1.54–3.12) over five years | [9] |
| Simonsen et al., 2025 | Danish–Norwegian new-user cohort, T2D | SGLT-2 inhibitors | Pooled HR 2.81 (1.67–4.75); +1.41 cases per 10,000 person-years | [10] |
| Tesfaye et al., 2025 | US claims, 482,912 matched pairs, T2D | SGLT-2 inhibitors | HR 1.85 (1.51–2.27); +0.29 per 1,000 person-years | [11] |
| Chou et al., 2025 | Multinational cohort; several strata | Non-semaglutide comparators | T2D with obesity, 3 years: HR 1.19 (0.78–1.82), not significant | [13] |
| Cai et al., 2025 | Large US network, new semaglutide users | Empagliflozin, sitagliptin, glipizide | Sensitive definition vs empagliflozin: HR 1.44 (0.78–2.68); specific definition: HR 2.27 (1.16–4.46) | [14] |
| Abbass et al., 2025 | Matched cohort, T2D and high BMI | Non-GLP-1 RA users | T2D, 5 years: RR 0.70 (0.523–0.937) | [15] |
| Noh et al., 2026 | UK CPRD new-user cohort, T2D | DPP-4 inhibitors | 1-year RR 2.56 (1.44–4.86); +11.3 per 100,000 | [12] |
| FDA RCT meta-analysis, 2026 | 126 trials; 134,253 patients; 15 probable events | Placebo or non-GLP-1 RA glucose-lowering medicine | 6.4 vs 3.8 events per 100,000 person-years (no HR published) | [1] |
| FDA Sentinel, 2026 | Adults with T2D initiating treatment, 2019–2024 | SGLT-2 or DPP-4 inhibitors | vs SGLT-2i: HR 1.19 (0.91–1.54); vs DPP-4i: HR 1.43 (1.02–2.01) | [1] |
What FDA actually found
Because individual trials contained few or no cases, FDA pooled 126 randomised trials across GLP-1 RA development programmes: 134,253 patients and 288,879 person-years of exposure, with 15 probable NAION events — ten on a GLP-1 RA, five on placebo, and none on another non-GLP-1 RA glucose-lowering medicine — producing the rates of 6.4 versus 3.8 per 100,000 person-years [1]. FDA did not publish a hazard ratio or confidence interval. Fifteen events is still a small numerator, but randomisation does much of the work that observational designs attempt after the fact.
A Sentinel cohort in adults with type 2 diabetes who started a GLP-1 RA, an SGLT-2 inhibitor or a DPP-4 inhibitor between 2019 and 2024 found much higher absolute rates, as expected in a less selected insured population: 30 to 32 events per 100,000 person-years with GLP-1 RAs, 31 with SGLT-2 inhibitors and 26 with DPP-4 inhibitors. There was no statistically significant increase versus SGLT-2 inhibitors (HR 1.19; 95% CI 0.91–1.54), but there was an increase versus DPP-4 inhibitors (HR 1.43; 95% CI 1.02–2.01) [1]. That pattern also appears in several published studies.
FDA reviewed reports in its Adverse Event Monitoring System, formerly FAERS, but found them hard to interpret because NAION risk factors overlap with the indicated conditions [1]. Animal data did not identify a mechanism [1]. The agency states that methodologically rigorous published studies consistently reported an increased risk compared with a DPP-4 or SGLT-2 inhibitor, generally consistent with its own analyses, and that NAION cases have been reported for all currently marketed GLP-1 RA products [1]. On that package, it required a Warnings and Precautions statement for the class.

Biological plausibility and the main confounders
A direct toxic effect of GLP-1 receptor agonism on the optic nerve has not been established. FDA's animal-data review did not identify a mechanism [1], and a 2026 consensus statement from the North American Neuro-Ophthalmology Society (NANOS) and the American Academy of Ophthalmology (AAO) does not treat a receptor-level injury as demonstrated [16].
The more discussed hypothesis is indirect: a rapid fall in blood glucose may alter osmotic balance or disc perfusion in a crowded, already vulnerable optic disc, in much the same way that rapid improvement in glycaemic control has been linked to early worsening of diabetic retinopathy, a risk already described in semaglutide cardiovascular outcomes trials and in product labelling [17][18]. The UK CPRD analysis is consistent with that idea, in that the association was stronger when haemoglobin A1c fell by at least one percentage point [12]. It remains a hypothesis, and it would not, on its own, explain events in people treated solely for weight management.
Confounding is substantial. Diabetes, hypertension, sleep apnoea, smoking, anaemia and kidney disease are both NAION risk factors and common in the treated population [1][6]. Sleep apnoea deserves particular care in case assessment, because it is itself an indication for at least one product in the class and a classic nocturnal risk factor for NAION. Detection bias is also likely after mid-2024: once a high-profile paper and subsequent regulatory reviews were in circulation, sudden visual symptoms were more likely to be investigated, coded and reported. None of this abolishes the signal. It does mean that a single spontaneous report will rarely settle causality on its own.
How other regulators have acted
Regulators have moved at different speeds, and they have not all drawn the class boundary in the same place.
PRAC concluded its review on 6 June 2025. After assessing non-clinical studies, clinical trials, post-marketing surveillance and the literature, it classified NAION as a very rare adverse reaction of semaglutide — meaning it may affect up to 1 in 10,000 people — and recommended that treatment be stopped if NAION is confirmed [2]. Several large epidemiological studies, PRAC said, suggested an approximately two-fold increase in risk in adults with type 2 diabetes, or about one additional case per 10,000 person-years [2]. The review began as a post-authorisation measure arising from a PSUR assessment [2]. EU product information for Ozempic, Rybelsus and Wegovy was updated on 30 September 2025 [5]. As of 10 November 2026, that completed EU review applies to semaglutide; a comparable completed EU class review covering tirzepatide, dulaglutide, liraglutide or orforglipron was not identified for this article.
At its May 2025 meeting, WHO's Advisory Committee on Safety of Medicinal Products recommended that the semaglutide risk-management plan include NAION as a potential risk, with any required additional pharmacovigilance activities [19]. MHRA issued a Drug Safety Update on 5 February 2026 for semaglutide only, with other GLP-1 RAs still under review [6]. From first UK authorisation in 2018 to 1 August 2025, the Yellow Card scheme had received three spontaneous reports suggestive of NAION, against an estimated 10.2 million packs dispensed over five years [6]. MHRA also warned that privately prescribed semaglutide may not appear in a patient's medical history [6].
Health Canada has already added NAION language to the verified monographs for Ozempic (authorised 13 July 2026; ophthalmologic warning dated April 2026) and Mounjaro (authorised 23 June 2026): urgent ophthalmological referral, and discontinuation if NAION is confirmed. The Ozempic text cites epidemiological evidence at a very rare frequency and notes that there is no identified time interval after treatment starts [17][18]. Australia's Therapeutic Goods Administration published a class-wide update on 23 July 2026, after advisory-committee advice that the evidence might support a signal for semaglutide but not for dulaglutide or tirzepatide [7][8]. Only semaglutide carries a special warning in section 4.4; dulaglutide, tirzepatide and liraglutide carry post-marketing statements in section 4.8 [7]. Swissmedic's November 2025 Vigilance-News recorded that the issue was under evaluation as of 2 October 2025 [20]; a subsequent official Swiss decision was not independently confirmed from primary product information for this article.
| Authority | Date of public action | Products in scope | Labelling position | Source |
|---|---|---|---|---|
| EMA / PRAC | 6 June 2025 (conclusion); EU product information updated 30 September 2025 | Semaglutide (Ozempic, Rybelsus, Wegovy) | Very rare adverse reaction; stop treatment if NAION is confirmed; about one additional case per 10,000 person-years | [2][5] |
| WHO ACSoMP | May 2025 meeting; news 27 June 2025 | Semaglutide | Recommended adding NAION as a potential risk in the risk-management plan | [19] |
| MHRA | 5 February 2026 | Semaglutide only; other GLP-1 RAs under review | Very rare association; urgent ophthalmology referral; discontinue if confirmed | [6] |
| Health Canada | Mounjaro monograph 23 June 2026; Ozempic monograph 13 July 2026 (ophthalmologic warning dated April 2026) | Semaglutide (Ozempic, verified); tirzepatide (Mounjaro, verified) | Urgent referral; discontinue if confirmed. Ozempic cites epidemiological evidence at very rare frequency | [17][18] |
| TGA | 23 July 2026 | Semaglutide, tirzepatide, dulaglutide, liraglutide | Class-wide update, with a section 4.4 warning only for semaglutide | [7] |
| FDA | 9 November 2026 | All GLP-1 RAs, including tirzepatide and orforglipron | Add potential increased risk to Warnings and Precautions; consider discontinuation unless benefits clearly outweigh the risk | [1] |
Products in scope, including oral and combination programmes
FDA's table of approved GLP-1 RAs is the operational list for US labelling [1]. It includes generic exenatide (the Byetta new drug application was voluntarily withdrawn in 2025 for reasons other than safety or effectiveness); the liraglutide products Victoza, Saxenda and Xultophy; Trulicity; Soliqua; Ozempic, Rybelsus and Wegovy; Mounjaro and Zepbound; and Foundayo (orforglipron), approved on 1 April 2026 [1][21]. Tirzepatide is included as a GIP and GLP-1 receptor agonist [1]. The class is therefore already wider than injectable peptide GLP-1 analogues used for diabetes.
That matters for products still in development. Oral small-molecule agonists, higher-dose or oral semaglutide programmes, dual and triple incretin agonists, and combinations with amylin analogues share a pharmacology that FDA has now treated as a class for NAION, even where the specific molecule has little dedicated epidemiology. Investigator's brochures, development core safety information and trial consent forms should be reviewed against the FDA communication, not left until first approval.
Pharmacovigilance implications
A class label built from trials and real-world evidence. Spontaneous reporting did not drive this decision. FDA found its own post-marketing cases difficult to interpret [1]; MHRA had only three suggestive Yellow Cards against millions of packs [6]. The useful evidence was a pooled trial analysis, a regulated real-world study, and a body of active-comparator observational literature. Signal-management files should be updated to reflect that hierarchy. Disproportionality statistics may now rise because of publicity, which is not the same as new evidence.
Reference safety information, CCDS and expectedness. Once the US Warnings and Precautions language is on the label, NAION becomes a listed event for US post-marketing reporting for every product in FDA's table. Until a company's core data sheet and local labels catch up, expectedness will differ by region and by product. In the EU, NAION is already a listed, very rare adverse reaction of semaglutide [2][5], but that listed status does not automatically extend to tirzepatide, dulaglutide, liraglutide or an unapproved molecule. For clinical trials, a case of NAION that is serious and not listed in the investigator's brochure remains a suspected unexpected serious adverse reaction (SUSAR) and must be expedited accordingly. The practical work is a coordinated RSI, CCDS and IB update, with a clear record of the date from which expectedness changed in each jurisdiction.
Coding and case follow-up. Reports will arrive as sudden vision loss, blurred vision, visual-field defect, optic neuropathy or a more specific NAION term. Intake should not depend on a single preferred term. A targeted follow-up questionnaire is now a basic control. Useful elements include laterality; whether the loss was sudden, painless and noticed on waking; ophthalmology confirmation, including disc appearance and whether the fellow eye shows a crowded disc; exclusion of arteritic anterior ischaemic optic neuropathy; time since treatment start and since the last dose increase; recent haemoglobin A1c trajectory; sleep apnoea, hypotension, anaemia, smoking and prior NAION; and the identity and source of the product, including whether it was branded, generic, compounded or suspected counterfeit. Causality assessment should address those confounders explicitly.
Aggregate reporting and the RMP. PSURs and PBRERs should carry a dedicated NAION discussion: cumulative cases with latency, confirmation status and product source; the evolving literature; the FDA meta-analysis and Sentinel results; and an explicit benefit-risk statement that keeps the absolute risk in view. Development safety update reports should do the same for pipeline programmes, including oral small molecules and combination or amylin products, even if the programme itself has no cases. In the EU, NAION has moved, for semaglutide, from a matter under review to a listed very rare reaction; the risk-management plan characterisation, and the need for additional pharmacovigilance activities such as targeted follow-up, should be revisited. WHO had already advised that the plan include NAION as a potential risk [19].
Trials, monitoring and consent. NANOS and AAO do not recommend routine pre-treatment screening for NAION; they do recommend urgent evaluation of sudden vision loss, and an individualised decision on whether to start, continue or stop therapy after an event [16]. FDA advises prompt referral and consideration of discontinuation unless the benefits of treatment clearly outweigh the risk, noting that a history of NAION increases the risk of recurrence [1]. Protocols should define an ophthalmology referral pathway and an adjudication route, rather than adding uninformative routine eye examinations. Informed-consent forms for ongoing and planned incretin trials should describe the potential rare risk, the symptoms that must be reported immediately, and the possibility that treatment would be stopped if NAION is confirmed.
Compounded and counterfeit products. FDA's concerns with unapproved GLP-1 drugs are already extensive: compounded products are not reviewed for safety, quality or effectiveness; salt forms of semaglutide have been used without a lawful basis that the agency recognises; dosing errors have led to hospitalisation; retatrutide and cagrilintide cannot be used in compounding under US federal law; and counterfeit Ozempic and fraudulent compounded labels have been found in the US supply chain [22]. As of 31 May 2026, FDA had received 990 adverse-event reports associated with compounded semaglutide and more than 730 with compounded tirzepatide, figures likely to under-represent the true number because many state-licensed pharmacies are not required to submit reports [22]. A NAION case on a compounded or counterfeit product cannot be assessed as if it were labelled use of the innovator medicine, but it still has to be followed up, and the source of the product has to be recorded.
Communication with healthcare professionals. The clinical message is consistent across regulators: this is a rare event; sudden, usually unilateral, painless visual loss needs urgent ophthalmological assessment; if NAION is confirmed, treatment should be stopped, or, in FDA's slightly more flexible wording, discontinuation should be considered unless benefits clearly outweigh the risk [1][2][6]. Benefit-risk for the approved uses has not been overturned. Patients with prior NAION, or with vision already reduced in one eye, need a more careful conversation before starting or continuing therapy [16].

A practical checklist for sponsors
| Lifecycle stage | Action |
|---|---|
| Core safety information | Update the CCDS/RSI and, for development products, the IB, to reflect a potential class risk of rare NAION. Record the date from which the event is considered listed in each core document [1][2] |
| Local labelling | Implement the US Warnings and Precautions language for every GLP-1 RA on the US market, including orforglipron and insulin combinations [1]. Align EU, UK, Canadian and Australian texts with the current, product-specific wording rather than assuming a single global sentence [2][6][7][17][18] |
| Expectedness and expedited reporting | Recalculate expectedness by product and country. Treat a serious NAION case as a SUSAR where the IB or local label does not yet list it |
| Case intake | Add a standing query for NAION and related optic-neuropathy and sudden-vision-loss terms. Do not rely on a single code |
| Follow-up | Deploy a targeted questionnaire covering ophthalmology confirmation, laterality and onset, "disc at risk," arteritic alternatives, glycaemic change, sleep apnoea and other vascular risk factors, and the source of the product |
| Signal and aggregate reporting | Recharacterise the signal in light of the FDA and PRAC conclusions. Add a standing NAION section to the PSUR/PBRER and DSUR, including literature, the 126-trial meta-analysis, Sentinel, and cumulative confirmed cases [1][2] |
| Risk-management plan | Revisit characterisation (potential versus identified; semaglutide versus other incretins). Consider targeted follow-up as an additional pharmacovigilance activity [19] |
| Clinical trials | Update informed consent; specify an urgent ophthalmology referral and adjudication pathway; do not add routine NAION screening without a clear purpose [16] |
| Pipeline incretins | Apply the same RSI and consent review to oral small molecules, dual and triple agonists, and amylin combinations, even if molecule-specific epidemiology is thin [1] |
| Compounded and diverted product | Ask every ocular-event reporter about the source of the medicine. Track compounded and suspected counterfeit cases separately from labelled use [22] |
| Medical information and risk communication | Brief healthcare professional and patient-facing channels on symptoms, referral, discontinuation advice and the low absolute risk. Keep statements consistent with the relevant label |
What is established, and what is not
It is established that NAION has been reported in patients treated with every currently marketed GLP-1 RA, that a pooled analysis of 126 randomised trials found a higher incidence with GLP-1 RAs than with comparators, and that several large new-user studies, and FDA's own Sentinel analysis versus DPP-4 inhibitors, have found an association [1][10][11][12]. It is established that the absolute risk is small: FDA's trial rates sit in the same range as the published background incidence in older adults, and the Nordic estimate of about one to two additional cases per 10,000 person-years is of the same order as PRAC's figure [1][2][10]. It is established that EMA, MHRA, Health Canada and the TGA had already acted, to differing extents, before FDA required a US class warning [2][6][7][17][18].
It is not established that GLP-1 receptor agonism injures the optic nerve by a defined biological mechanism [1][16]. It is not established that every molecule in the class carries the same magnitude of risk: the richest epidemiology is still for semaglutide, some well-conducted studies are null, and FDA's Sentinel contrast with SGLT-2 inhibitors was not statistically significant [1][13][14][15]. It is not established that the US class-wide Warnings and Precautions statement will be mirrored, in the same terms, by every other major regulator.
None of that is a reason to wait. The US label is changing for the whole class, expectedness is changing with it, and the operational work — RSI, case follow-up, periodic reports, consent and a consistent conversation with prescribers — is already due.
References
- FDA: Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition, 9 November 2026
- EMA: PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines Ozempic, Rybelsus and Wegovy, 6 June 2025
- Hathaway JT et al. Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide. JAMA Ophthalmol. 2024;142(8):732-739
- Danish Medicines Agency: Suspicion of rare eye condition from Ozempic use to be investigated further, 16 December 2024
- Danish Medicines Agency: Updates of 2 October 2025, noting that EMA product information for Rybelsus, Ozempic and Wegovy was updated on 30 September 2025
- MHRA Drug Safety Update: Semaglutide (Wegovy, Ozempic and Rybelsus): risk of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION), 5 February 2026
- Therapeutic Goods Administration: GLP-1 RAs and rare vision disorder, 23 July 2026
- Therapeutic Goods Administration: ACM meeting statement, Meeting 53, 3 October 2025
- Grauslund J et al. Once-weekly semaglutide doubles the five-year risk of nonarteritic anterior ischemic optic neuropathy in a Danish cohort of 424,152 persons with type 2 diabetes. Int J Retina Vitreous. 2024;10:97
- Simonsen E et al. Use of semaglutide and risk of non-arteritic anterior ischemic optic neuropathy: A Danish–Norwegian cohort study. Diabetes Obes Metab. 2025;27(6):3094-3103
- Tesfaye H, Paik JM, Wexler DJ, et al. GLP-1RA and the risk of non-arteritic anterior ischaemic optic neuropathy in patients with type 2 diabetes: A population-based study. Diabetes Obes Metab. 2025
- Noh Y, Yin H, Ben Ghezala I, Yu OHY, Suissa S, Azoulay L. Glucagon-Like Peptide 1 Receptor Agonists and Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients With Type 2 Diabetes. Diabetes Care. 2026;49(5):763
- Chou CC et al. Association between Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy. Ophthalmology. 2025;132(4):381-388
- Cai CX et al. Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy. JAMA Ophthalmol. 2025
- Abbass NJ, Nahlawi R, Shaia JK, et al. The Effect of Semaglutide and GLP-1 RAs on Risk of Nonarteritic Anterior Ischemic Optic Neuropathy. Am J Ophthalmol. 2025;274:24-31
- North American Neuro-Ophthalmology Society and American Academy of Ophthalmology. Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Non-Arteritic Anterior Ischemic Optic Neuropathy: A Consensus Statement, 2026
- Ozempic (semaglutide injection) Product Monograph, Novo Nordisk Canada. Date of Authorization: 13 July 2026
- Mounjaro (tirzepatide injection) Product Monograph, Eli Lilly Canada. Date of Authorization: 23 June 2026
- WHO: The use of semaglutide medicines and risk of non-arteritic anterior ischemic optic neuropathy (NAION), 27 June 2025
- Swissmedic Vigilance-News, Edition 35, November 2025
- FDA: Approves First New Molecular Entity Under National Priority Voucher Program (orforglipron, Foundayo), 1 April 2026
- FDA: Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (adverse-event counts as of 31 May 2026)
Safety Strategy · Pharmacovigilance and safety risk management · Vaud, Switzerland
This article is for information only and is not medical or regulatory advice.
Related services: signal management and benefit-risk assessment, risk management (EU RMP, US REMS, aRMMs) and regulatory filings including DSURs.
Follow Safety Strategy on LinkedIn (opens in a new tab) for new articles and updates. Back to all news